1
* Not all systems shown available worldwide.
2
Budi Gunadi Sadikin
Minister of Health
Republic of Indonesia
3
Histórico do programa
2006
A cepheid coloca os primeiros sistemas GeneXpert®
2006
A OMS lança a estratégia Stop TB no Dia Mundial da TB
2006
Cepheid, FIND, University of Medicine and Dentistry of New Jersey (Rutgers University), and NIAID collaborate to develop Xpert® MTB/RIF* for TB with a grant from the Bill & Melinda Gates Foundation
2009–2010
É lançado o Xpert MTB/RIF e obtém a recomendação da OMS
Acesso global
2011
A Cepheid estabelece oficialmente o Programa de Acesso Global
2006
Em resposta às taxas elevadas de coinfeção por TB-VIH nos países de Acesso Global, a Cepheid e a “FIND” colaboram para desenvolver o teste de carga viral de HIV-1 Xpert.
2014
Xpert® HPV* and Xpert HIV-1 VL* tests launch
2015
Cepheid develops and launches Xpert® Ebola test to respond to West African outbreak with funding support from the Paul G. Allen and Bill & Melinda Gates Foundations
2016
WHO prequalifies Xpert HIV-1 Qual*
2017
WHO prequalifies Xpert HCV VL*, Xpert HIV-1 VL*, and Xpert HPV*; Xpert® MTB/RIF Ultra* launches and gets WHO endorsement
2020
Xpert® MTB/XDR* launches to detect multidrug-resistant TB with new 10-color multiplexing technology
2020
Xpert® Xpress SARS-CoV-2" launches
Programa de Acesso Global hoje
GeneXpert systems available in multiple modular configuration options 15 tests available under Global Access Program, 7 of which are endorsed or pre-qualified by WHO
* CE-IVD. Dispositivo médico para diagnóstico in vitro. Poderá não estar disponível em todos os países. Não está disponível nos Estados Unidos da América.
IVD. Dispositivo médico para diagnóstico in vitro. Poderá não estar disponível em todos os países
^ Para utilização sob autorização em caso de emergência apenas nos Estados Unidos da América
Dr. Tereza Kasaeva, Director, Global Tuberculosis Programme, WHO World TB Day 2023, Interview with Dr. Tereza Kasaeva
https://www.youtube.com/watch?v=AL_t8LZkD8Y
2. Journal of Benefit-Cost Analysis (2023) https://www.cambridge.org/core/journals/journal-of-benefit-cost-analysis/article/one-million-lives-saved-per-year-a-costbenefit-analysis-of-the-global-plan-to-end-tuberculosis-20232030-and-beyond/A74F0D10F1017092A250EB604ED39B1B
3. Message from the Executive Director: Global Fund Investments in Health and Laboratory-related Equipment; 21 de Janeiro de 2024
https://www.theglobalfund.org/en/oig/updates/2024-01-26-message-executive-director-global-fund-investments-health-laboratory-related-equipment/
4. Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria.
From the TB Innovation Summit https://www.stoptb.org/news/global-health-and-business-leaders-pledge-major-commitments-to-end-tuberculosis